Simulations Plus (SLP) to Release Earnings on Thursday

Simulations Plus (NASDAQ:SLP - Get Free Report) is projected to issue its quarterly earnings data after the market closes on Thursday, April 3rd. Analysts expect the company to announce earnings of $0.25 per share and revenue of $21.93 million for the quarter.

Simulations Plus Price Performance

NASDAQ SLP traded up $0.09 during trading on Friday, reaching $24.29. 247,486 shares of the company's stock were exchanged, compared to its average volume of 173,381. The business has a 50 day moving average price of $30.80 and a 200-day moving average price of $30.53. The stock has a market capitalization of $488.03 million, a P/E ratio of 60.73 and a beta of 0.89. Simulations Plus has a fifty-two week low of $23.63 and a fifty-two week high of $51.22.

Insider Activity at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the sale, the director now owns 3,402,584 shares in the company, valued at $115,381,623.44. The trade was a 0.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 19.40% of the stock is currently owned by corporate insiders.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. William Blair reissued an "outperform" rating on shares of Simulations Plus in a report on Wednesday, January 8th. KeyCorp upped their price objective on shares of Simulations Plus from $35.00 to $37.00 and gave the company an "overweight" rating in a report on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $49.40.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.